Abbott India Q4 FY25 Earnings Results: Profit jumps 28% YoY to ₹367 Crore

Abbott India's shares saw a sharp increase of nearly 4% on Friday after the company announced a significant rise in its quarterly profit. During the trading session, the stock climbed as much as 3.86%, reaching ₹31,500 per share. This marked the company’s biggest intraday gain since April 15 of this year. Later in the session, the stock trimmed some of its gains but was still trading 1.09% higher at ₹30,660. In comparison, the benchmark Nifty 50 index was down by 0.23% at the same time.

So far in 2025, Abbott India’s share price has increased by around 3%, whereas the Nifty 50 has seen a decline of 5.75%. The company currently has a market capitalisation of ₹65,235.36 crore. It is worth noting that the stock reached its highest-ever price of ₹31,898.9 on March 5, 2025.

Financial Performance in Q4FY25

Abbott India, a subsidiary of global healthcare company Abbott Laboratories, reported a strong 28% year-on-year increase in its profit after tax (PAT) for the quarter ending March 31, 2025. The profit after tax (PAT) rose to ₹367 crore in Q4FY25, up from ₹287 crore in the same quarter the previous year. The company’s revenue from operations also showed a healthy increase, rising to ₹1,605 crore during the quarter compared to ₹1,439 crore in the year-ago period.

In terms of expenditure, Abbott India saw its total expenses grow by 6%, amounting to ₹1,197.90 crore in Q4FY25. This was higher than the ₹1,130.10 crore spent during the corresponding quarter of the last financial year. The company’s strong performance reflects its continued focus on operational efficiency and market expansion.

Read More, NCC Q4 FY25 Earnings Results Out: Company Declares Dividend of ₹2.20/Share!   

Full-Year Results for FY25

For the entire financial year ended March 31, 2025, Abbott India recorded a net profit of ₹1,414.44 crore. This represents a 17.7% increase compared to the net profit of ₹1,201.22 crore in the previous financial year. The company also reported a rise in annual revenue, which reached ₹6,409 crore in FY25, up from ₹5,849 crore in FY24. These figures highlight the company’s consistent financial growth and its ability to maintain profitability in a competitive market environment.

Dividend Declaration for FY25

In addition to its strong financial results, Abbott India’s board of directors has recommended a final dividend of ₹475 per equity share for the financial year 2025. The face value of each share is ₹10. The dividend proposal is subject to approval by the shareholders at the company’s upcoming AGM (Annual General Meeting). 

Overview of Abbott India's Business Operations

Abbott India is a leading multinational pharmaceutical company with a strong presence in the Indian healthcare sector. It operates its own manufacturing facility located in Goa and also partners with several contract and third-party manufacturers across the country. The company’s products are mainly distributed through a network of independent distributors, serving customers across various regions of India.

Conclusion

Abbott India’s impressive fourth-quarter and full-year results showcase the company’s financial strength and strategic growth in a challenging market. With a robust profit increase, rising revenue, and a generous dividend payout, the company continues to reinforce investor confidence.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.              

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.